CompletedPhase 3NCT02039726
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Daiichi Sankyo
- Principal Investigator
- Jorge E. Cortes, MDM.D. Anderson Cancer Center
- Intervention
- Quizartinib(drug)
- Enrollment
- 367 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2020
Study locations (30)
- City of Hope National Medical Center, Duarte, California, United States
- University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCLA Medical Center, Los Angeles, California, United States
- UC Davis Cancer Center, Sacramento, California, United States
- Stanford University Medical Center Stanford Comprehensive Cancer Center, Stanford, California, United States
- Yale University, New Haven, Connecticut, United States
- Emory Winship Cancer Institute, Atlanta, Georgia, United States
- University of Illinois at Chicago, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Franciscan Alliance, Indianapolis, Indiana, United States
- University of Kansas Medical Center Research Institute Inc, Westwood, Kansas, United States
- LSU Health Sciences Center Feist Weiller Cancer Center, Shreveport, Louisiana, United States
- University of Maryland, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Health System, Ann Arbor, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02039726 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo